Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Exp Hematol. 2012 Aug 10;40(12):974–982.e1. doi: 10.1016/j.exphem.2012.08.002

Table 3.

Cox proportional hazard regression models for overall survival and nonrelapse mortality

	Overall survival			Nonrelapse mortality
Factor	Deaths/patients at risk	HR (95% CI)	p Value	Deaths/patients at risk	HR (95% CI)	p Value
Low CLA⁺ and low α₄β₇⁺ Tregs	17/31	1		8/31	1
High CLA⁺^* or high α₄β₇⁺ Tregs^†	12/43	0.44 (0.20–0.99)	0.046	2/43	0.12 (0.02–0.61)	0.011
Myeloablative	14/45	1		6/45	1
Reduced intensity	15/29	1.23 (0.53–2.90)	0.630	4/29	1.09 (0.22–5.53)	0.918
Related donor	22/50	1		6/50	1
Unrelated donor	7/24	0.24 (0.05–1.22)	0.085	4/24	0.22 (0.02–3.02)	0.255
Peripheral blood stem cells	22/55	1		6/55	1
Bone marrow or cord blood	7/19	3.41 (0.67–17.4)	0.140	4/19	9.78 (0.68–140)	0.093
Grade 0–I aGVHD	8/17	1		2/17	1
Grade II–IV aGVHD	21/57	0.65 (0.28–1.52)	0.324	8/57	0.70 (0.14–3.60)	0.667

HR 5 hazard ratio.

^*

High CLA⁺ Tregs: CLA⁺ Tregs/Tregs ≥3.25%.

^†

High α₄β₇⁺ Tregs: α₄β₇⁺ Tregs/Tregs ≥21.8%.